In an interview with ET Now, Glenn Saldanha, Chairman and Managing Director, Glenmark, gives his views on the company's strategies. Excerpt...

Glenmark has filed arbitration claims against Napo Pharmaceuticals for ending a contract to develop and market diarrhea drug.

Glenmark and Salix have also entered into a commercial supply agreement for Crofelemer active pharmaceutical ingredient.

Glenmark’s partners — US-based Napo Pharmaceuticals and Salix Pharmaceuticals — have announced completion of phase-III trials for the drug ...

Glenmark Pharmaceuticals has completed the third phase of human trials of Crofelemer, a new drug to treat HIV-related diarrhoea that could ...

Glen Saldanha, Managing Director & CEO, Glenmark Pharmaceuticals speaks to ET Now. Excepts from the interview.

Glenmark Pharmaceuticals Ltd has reported new development that should accelerate the launch of Crofelemer.

The lights may be going out on Wall Street, where for the first time since World War II bankers are on the verge of earning less from initi...

Domestic pharmaceutical major Nicholas Piramal India has entered into a plant screening agreement with San Francisco-based Napo Pharmaceuti...

Glenmark Pharmaceuticals Ltd on Friday said it has successfully produced active pharmaceutical ingredient (API), crofelemer, used for chron...

Glenmark Pharmaceuticals Ltd today said it has received approval from the Drug Controller General of India (DCGI) to initiate phase II tria...